TW202340210A - 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑 - Google Patents

1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑 Download PDF

Info

Publication number
TW202340210A
TW202340210A TW112102814A TW112102814A TW202340210A TW 202340210 A TW202340210 A TW 202340210A TW 112102814 A TW112102814 A TW 112102814A TW 112102814 A TW112102814 A TW 112102814A TW 202340210 A TW202340210 A TW 202340210A
Authority
TW
Taiwan
Prior art keywords
pyridine
dimethyl
pyrrolo
pyrido
dihydro
Prior art date
Application number
TW112102814A
Other languages
English (en)
Chinese (zh)
Inventor
喬治 A 朵合蒂
維克瑞 巴特
派翠克 布洛迪
玉嘉 戴
建春 龔
安卓 S 朱德
安德魯 J 索爾斯
俞一贇
Original Assignee
美商艾伯維有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾伯維有限公司 filed Critical 美商艾伯維有限公司
Publication of TW202340210A publication Critical patent/TW202340210A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW112102814A 2022-01-21 2023-01-19 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑 TW202340210A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263267018P 2022-01-21 2022-01-21
US63/267,018 2022-01-21

Publications (1)

Publication Number Publication Date
TW202340210A true TW202340210A (zh) 2023-10-16

Family

ID=85382827

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112102814A TW202340210A (zh) 2022-01-21 2023-01-19 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑

Country Status (13)

Country Link
US (3) US11964990B2 (cg-RX-API-DMAC7.html)
EP (1) EP4466273A1 (cg-RX-API-DMAC7.html)
JP (2) JP7714811B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240136972A (cg-RX-API-DMAC7.html)
CN (1) CN119053610A (cg-RX-API-DMAC7.html)
AR (1) AR128310A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023210279A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242074A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024009334A2 (cg-RX-API-DMAC7.html)
IL (1) IL312709A (cg-RX-API-DMAC7.html)
MX (1) MX2024008840A (cg-RX-API-DMAC7.html)
TW (1) TW202340210A (cg-RX-API-DMAC7.html)
WO (1) WO2023141536A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202340210A (zh) * 2022-01-21 2023-10-16 美商艾伯維有限公司 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑
CN117820134A (zh) * 2024-01-10 2024-04-05 山东盛安贝新材料有限公司南京分公司 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002032A (es) 2017-08-23 2020-09-17 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de bcl-2.
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
MX2022010410A (es) 2020-02-24 2022-12-07 Guangzhou Lupeng Pharmaceutical Company Ltd Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2.
TW202340210A (zh) * 2022-01-21 2023-10-16 美商艾伯維有限公司 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑

Also Published As

Publication number Publication date
AU2023210279A1 (en) 2024-05-23
JP2025504382A (ja) 2025-02-12
IL312709A (en) 2024-07-01
CA3242074A1 (en) 2023-07-27
AR128310A1 (es) 2024-04-17
CO2024009334A2 (es) 2024-07-18
US20230234971A1 (en) 2023-07-27
KR20240136972A (ko) 2024-09-19
US20250066388A1 (en) 2025-02-27
MX2024008840A (es) 2024-07-25
EP4466273A1 (en) 2024-11-27
JP7714811B2 (ja) 2025-07-29
WO2023141536A1 (en) 2023-07-27
US11964990B2 (en) 2024-04-23
US20260028356A1 (en) 2026-01-29
CN119053610A (zh) 2024-11-29
JP2025160251A (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
JP7356450B2 (ja) 酸性または低酸素の疾患組織を含む疾患の治療のための化合物、組成物、及び方法
JP7784041B2 (ja) がんの治療のためのent阻害剤としての大環状ジアミン誘導体、及びそれとアデノシン受容体拮抗薬との組合せ
CN104470919B (zh) 作为pad4抑制剂的2-(氮杂吲哚-2-基)苯并咪唑
JP2025160251A (ja) 1,3,4,7-テトラヒドロ-2H-ピロロ[3’,2’:5,6]ピリド[2,3-B][1,4]オキサアゼピンBcl-2阻害剤
JP2025114615A (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
CN104603146B (zh) 环肽类化合物及其作为药物的用途
TW201920194A (zh) 大環mcl-1抑制劑及使用方法
EP2489360A1 (en) Stabilized MAML peptides and uses thereof
EA021538B1 (ru) Ингибиторы вируса гепатита с
WO2010084798A1 (ja) 3環性化合物
WO2021161105A1 (en) P2x3 modulators
CN117677627A (zh) 分拣蛋白活性调节剂
JP2021531310A (ja) ボロン酸誘導体
TW202333663A (zh) Rxfp1促效劑
KR20160067840A (ko) 펩티드-올리고우레아 키메라 화합물 및 이의 사용 방법
HUT52525A (en) Process for producing retroviral proteaz-inhibitors and pharmaceutical compositions containing them as active components
JPH06501681A (ja) レトロウイルス・プロテアーゼの阻害剤
EP0416740A2 (en) Novel compounds with renin-inhibiting activity
US20050113397A1 (en) Imidazo[1,2-a]pyridine derivative
KR20190032534A (ko) C5a 수용체 길항제로서의 시클릭 펩티드
JP2020533374A (ja) 環状ペプチド抗生物質
CN116768967A (zh) 氘代内酰胺类化合物及其制备方法、组合物和用途
KR100238894B1 (ko) 시클로 펩티드
EP2975046A1 (en) Novel compounds
CA3136351C (en) Benzimidazole derivatives and their uses